| Literature DB >> 33956183 |
Tatsuya Fukase1, Tomotaka Dohi2, Yoshiteru Kato1, Yuichi Chikata1, Norihito Takahashi1, Hirohisa Endo1, Shinichiro Doi1, Hiroki Nishiyama1, Iwao Okai1, Hiroshi Iwata1, Shinya Okazaki1, Kikuo Isoda1, Katsumi Miyauchi1, Hiroyuki Daida1, Tohru Minamino1,3.
Abstract
Little is known about the prognostic impact of high-sensitivity C-reactive protein (hs-CRP) levels on causes of death during long-term follow-up. We, therefore, investigated the associations between hs-CRP and clinical outcomes in the patients with intermittent claudication. Three hundred thirty-five consecutive patients (mean age, 72 ± 8 years, 82% men) undergoing first intervention for de novo iliac and/or femoropopliteal artery lesions from 2009 to 2020 were studied. Patients were divided into 2 groups based on the optimal cutoff value of hs-CRP (> or ≤ 0.15 mg/dL). The median follow-up duration was 3.6 years (interquartile range, 1.0-6.2 years). Although the cumulative incidence rate of major adverse cardiovascular limb events was not significantly different between the higher and lower hs-CRP groups (29.0 and 22.1%, respectively; log-rank test, p = 0.410), that of all-cause death was significantly higher in the higher hs-CRP group than in the lower hs-CRP group (18.7 vs. 5.8%, log-rank test, p = 0.007), even in cardiovascular-related death and malignancy-related death (log-rank test, p = 0.030 and 0.046, respectively). Higher hs-CRP levels at the time of intervention were significantly associated with higher frequency of all-cause death, even after adjusting for other risk factors (hazard ratio 2.79; 95% confidence interval 1.66-7.17, p = 0.024). In addition, malignancy-related death was most frequent as high as 60% (21/35 deaths), and elevated hs-CRP levels and the Brinkman index were strongly independent predictors of malignancy-related death. In conclusion, elevated hs-CRP levels were significantly associated with cardiovascular-related and malignancy-related deaths in patients with intermittent claudication. Furthermore, the result that cancer mortality exceeds cardiovascular mortality is different from previous reports, so the present findings warrant further investigation.Entities:
Keywords: Cardiovascular-related death; High-sensitivity C-reactive protein; Intermittent claudication; Malignancy-related death
Mesh:
Substances:
Year: 2021 PMID: 33956183 DOI: 10.1007/s00380-021-01863-6
Source DB: PubMed Journal: Heart Vessels ISSN: 0910-8327 Impact factor: 2.037